Back from CES Las Vegas Its a market thats waiting

Back from CES Las Vegas: “It’s a market that’s waiting for us,” welcome the participants – Sud Ouest

A crazy week in which we don't sleep much, but sometimes it saves a lot of time. For attendees at the Consumer Electronics Show (CES) in Las Vegas, the results are positive. More than twenty start-ups from New…

A crazy week in which we don't sleep much, but sometimes it saves a lot of time. For attendees at the Consumer Electronics Show (CES) in Las Vegas, the results are positive. More than twenty startups from Nouvelle-Aquitaine traveled to Nevada, sponsored by the region and its partners, including French Tech Bordeaux. Pierre Husson, co-founder of Rematch, returned to Bordeaux with stars in his eyes, ready to conquer the American market. “I have already had the opportunity to go to Vivatech in Paris or another trade fair in Lisbon, but this is really impressive,” he emphasizes. From 9 a.m. to 6 p.m. you have to be at your best. We only have two minutes to eat a sandwich and have to respond to the people crowding the stand. »

The CES enabled the three Rematch employees to get to know “soccer moms and dads,” the parents who support their children on the sidelines. “They sometimes spend thousands of euros to enable their children to practice their sport. They came to us to tell us that they were ready to film with Rematch. This is a market that is waiting for us. »

“The Good Actors”

Soufiane Ajana, founder of Retinov, an artificial intelligence-based tool for preventing age-related macular degeneration (AMD), made so many promising contacts that he stayed in the United States to make the most of your participation in the show. “I got to know the pensioners’ association,” he explains. That's the good thing about CES: we meet the right players. »

The young business leader received a visit at his stand in particular from the president of the world's leading manufacturer of retina cameras, a potential important partner for his activities. Soufiane Ajana also took advantage of his stay to start a clinical trial of his solution, essential for approval by the Food and Drug Administration (FDA). And it continues its efforts to establish itself in the American market with a fundraising effort.